We thank Timothy Byers, MD, MPH, for his contributions as an American Cancer Society Cancer Screening Guidelines Development Member. DISCLOSURES: Dr. Flowers has received consulting fees from Celgene Corporation; Spectrum; Seattle Genetics, Inc; OptumRx; Clinical Care Options; and Education Concepts Group. He has performed contracted research for Millennium Pharmaceuticals, Celgene Corporation, Spectrum, Gilead Pharmaceuticals, and Janssen Pharmaceuticals. Dr. Gazelle is a consultant to GE Healthcare. His work for GE Healthcare is not directly related to this article. Dr. Kelsey is employed by Eli Lilly and Company.
American Cancer Society lung cancer screening guidelines†
Article first published online: 11 JAN 2013
Copyright © 2013 American Cancer Society, Inc.
CA: A Cancer Journal for Clinicians
Volume 63, Issue 2, pages 106–117, March/April 2013
How to Cite
Wender, R., Fontham, E. T. H., Barrera, E., Colditz, G. A., Church, T. R., Ettinger, D. S., Etzioni, R., Flowers, C. R., Scott Gazelle, G., Kelsey, D. K., LaMonte, S. J., Michaelson, J. S., Oeffinger, K. C., Shih, Y.-C. T., Sullivan, D. C., Travis, W., Walter, L., Wolf, A. M. D., Brawley, O. W. and Smith, R. A. (2013), American Cancer Society lung cancer screening guidelines. CA: A Cancer Journal for Clinicians, 63: 106–117. doi: 10.3322/caac.21172
- Issue published online: 2 MAR 2013
- Article first published online: 11 JAN 2013
- lung neoplasms;
- radiation dosage;
- randomized controlled trials as topic;
- risk reduction behavior;
- computed tomography;
- adverse effects;
- lung cancer screening
Findings from the National Cancer Institute's National Lung Screening Trial established that lung cancer mortality in specific high-risk groups can be reduced by annual screening with low-dose computed tomography. These findings indicate that the adoption of lung cancer screening could save many lives. Based on the results of the National Lung Screening Trial, the American Cancer Society is issuing an initial guideline for lung cancer screening. This guideline recommends that clinicians with access to high-volume, high-quality lung cancer screening and treatment centers should initiate a discussion about screening with apparently healthy patients aged 55 years to 74 years who have at least a 30–pack-year smoking history and who currently smoke or have quit within the past 15 years. A process of informed and shared decision-making with a clinician related to the potential benefits, limitations, and harms associated with screening for lung cancer with low-dose computed tomography should occur before any decision is made to initiate lung cancer screening. Smoking cessation counseling remains a high priority for clinical attention in discussions with current smokers, who should be informed of their continuing risk of lung cancer. Screening should not be viewed as an alternative to smoking cessation. CA Cancer J Clin 2013;. © 2013 American Cancer Society.